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Abstract
We evaluated the influence of hypnotizability, pain expectation, placebo analgesia in wak-
ing and hypnosis on tonic pain relief. We also investigated how placebo analgesia affects
somatic responses (eye blink) and N100 and P200 waves of event-related potentials
(ERPs) elicited by auditory startle probes. Although expectation plays an important role in
placebo and hypnotic analgesia, the neural mechanisms underlying these treatments are
still poorly understood. We used the cold cup test (CCT) to induce tonic pain in 53 healthy
women. Placebo analgesia was initially produced by manipulation, in which the intensity of
pain induced by the CCT was surreptitiously reduced after the administration of a sham
analgesic cream. Participants were then tested in waking and hypnosis under three treat-
ments: (1) resting (Baseline); (2) CCT-alone (Pain); and (3) CCT plus placebo cream for
pain relief (Placebo). For each painful treatment, we assessed pain and distress ratings,
eye blink responses, N100 and P200 amplitudes. We used LORETA analysis of N100 and
P200 waves, as elicited by auditory startle, to identify cortical regions sensitive to pain
reduction through placebo and hypnotic analgesia. Higher pain expectation was associated
with higher pain reductions. In highly hypnotizable participants placebo treatment produced
significant reductions of pain and distress perception in both waking and hypnosis condition.
P200 wave, during placebo analgesia, was larger in the frontal left hemisphere while pla-
cebo analgesia, during hypnosis, involved the activity of the left hemisphere including the
occipital region. These findings demonstrate that hypnosis and placebo analgesia are differ-
ent processes of top-down regulation. Pain reduction was associated with larger EMG star-
tle amplitudes, N100 and P200 responses, and enhanced activity within the frontal, parietal,
and anterior and posterior cingulate gyres. LORETA results showed that placebo analgesia
modulated pain-responsive areas known to reflect the ongoing pain experience.
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Introduction
Human pain is a potent stressor with immediate relevance to survival and is believed to be a
multi-faceted protective experience involving the activity of sensory-discriminative, affective-
emotional, attentional-cognitive, behavioral and social learning systems [1–3]. Multiple psy-
chological factors have been suggested to modulate the magnitude of pain, i.e., past experience
[4, 5], classical conditioning [6–13], suggestibility [14, 15], expectancy [16], and ritualistic ther-
apeutic acts [14, 17, 18]. This type of modulation is believed to happen through a top-down
neurophysiological process that, when activated by one or more of the above mentioned fac-
tors, may produce neurophysiological changes that affect pain perception. The use of placebos
and hypnosis represents two ways of how the top-down control can modulate pain perception,
but the research of placebo and hypnosis often follows two separate tracks and their neurobio-
logical similarities and differences are yet not fully understood. We have known, for a long
time, that hypnotic analgesia is not a variant on placebo analgesia since highly hypnotizable
individuals report feeling less pain during hypnosis than during placebo condition [19], sug-
gesting that the effects of placebo and hypnosis analgesia are at least in part separate processes.
A recent literature review on brain activity changes to placebo and hypnotic analgesia has
highlighted similarities and differences between these two treatments [20]. First, these treat-
ments produce similar changes in the activity of a number of brain regions labeled as pain net-
work (i.e., somatosensory cortex, ACC, insula, thalamus, and prefrontal cortex). The activation
of prefrontal cortex is necessary for cognitive evaluation and plays a leading role during both
placebo and hypnotic analgesia treatments [21–24]. Pain relief elicited through these treat-
ments are mediated by dopaminergic activity in the prefrontal cortex [25–28] and caused by
changes in expectation [29, 30]. Second, the major differences between these two treatments lie
in the fact that placebo analgesia produces functional changes in several parts of the limbic sys-
tem (i.e., amygdala, hypothalamus and hippocampus, periaqueductal gray, nucleus accum-
bens). In contrast, hypnosis causes changes of activity in the occipital areas which are elicited
by mental imagery [31–33] and basal ganglia which operate in the voluntary movement regula-
tion [32, 34, 35].
The startle response is a fast defensive mechanism consisting of sequential sudden contrac-
tions of somatic muscles and is usually evoked by acoustic stimuli, with the likely purpose of
facilitating the flight reaction and/or protecting the body from sudden attack. It has been
proved that positive emotional states attenuate/inhibit defensive reflexes and that negative
states enlarge/facilitate defensive reflexes [36]. Such affective startle modulation has been
explained in terms of motivational priming: aversive emotional stimuli prime the defensive
motivational system and, thereby, facilitate defensive reflexes, whereas appetitive emotional sti-
muli inhibit defensive reflexes [36]. Although startle responses are muscular and event-related
potentials (ERPs) are neural, research has demonstrated that N100 and P200 waves of the
ERPs can be considered electrocortical indicators of the startle response [37–39], but little
effort has been devoted to parallel EMG startle with ERP responses [40]. Startle responses to
pulse-alone stimuli and ERP responses are also sensitive to arousal and affective states [41–44].
The N100 wave of the ERPs reflects the processing of the auditory stimulus’s physical features
(e.g., the intensity) [45], and, therefore, is a measure of the initial registration and attribute
selection of an auditory stimulus [46]. The P200 wave of the ERP is thought to represent a later
stage of stimulus processing and is viewed as an index of both sensory processing and cognitive
demands as the stimulus classification process [47]. Thus is not surprising that many studies
have shown that negatively charged stimuli elicit larger eye-blink reflexes than positively ones
[48–51] and that the N100 and P200 waves of the ERPs to auditory startles are sensitive to
emotional and arousal components of the stimulation. [44]. Negative and positive emotional
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stimuli usually elicit larger N100 and P200 amplitudes than neutral ones [52] in participants
highly sensitive to punishment [53].
Research has shown that eye-blink startle response is modulated by the attention devoted
to the startle probe [54] or engagement in a mentally demanding task [55]. For example, the
hand blink reflex has been recently found of significantly greater magnitude when the stimu-
lated hand is near to the face than when it is far [56]. These findings demonstrate that brain-
stem activities mediating defensive reflexes can receive a top-down modulation to select
adequately the external potential threats. Moreover, factors such as expectation [57] and
hypnotizability can affect both pain sensation and startle responses [58–62]. Although
research has demonstrated that fear-evoking stimuli consistently potentiate the magnitude
of the blink reflex [36, 63–66], studies investigating the pain potentiation of the startle
response has produced only inconclusive results. Some of them have reported no pain
potentiation of the startle response, regardless of the stimulus intensity and the subjects’
sensitivity to startle modulation [67, 68]. Research using the classic Cold Pressor Test (CPT)
has also produced inconclusive results [69, 70]. One study has reported a reduction in startle
magnitude [71], another study has shown a significant potentiation of the startle response
[72], and a more recent study has observed no significant effects [73]. Thus, in the present
study, to disentangle these contrasting results, we evaluated how tonic cold pain can influ-
ence motor and ERP components of the auditory startle response (ASR). Furthermore, hyp-
notic analgesia is one of the most reliable hypnotic phenomena [61, 74–78] and, although
the influence of cognition and attention in placebo and hypnosis analgesia have been dem-
onstrated, the neural mechanisms underlying to these two treatments are still poorly under-
stood. Therefore, aim of the present study was an attempt to evaluate how hypnotic
susceptibility, pain expectation, hypnosis and placebo treatments can influence tonic pain
relief and how this effect is reflected on eye-blink and ERP components of the ASR. To
induce tonic pain we used the cold cup test (CCT) [79], requiring to hold in the right hand
an iced water plastic cup at -10°C.
In the present study placebo analgesia was initially produced by a manipulation procedure
in which participants were simply fooled into thinking that a sham “analgesic cream” was
working to reduce their pain perception. The noxious-stimulus strength was then restored to
its original level and delivered during a placebo cream treatment (Placebo) and a painful
cream-free intervention (Pain), with a pre-stress Baseline serving as a control.
On the basis of our previous hypnotizability startle findings [60], we expected that hypnotiz-
ability and pain reduction should be associated with enhanced inhibitory responses, i.e.,
smaller ASRs, and smaller N100 and P200 ERP waves. Mainly, we expected that high hypnotiz-
able (HH) participants, during the Baseline and Placebo, as compared to the Pain, should
exhibit greater reductions of pain and distress scores with smaller ASRs and ERP amplitudes.
A further aim of the present study was to evaluate: (1) how placebo treatment during waking
may differ from placebo treatment during hypnosis; (2) how individual differences in pain
expectation and hypnotizability may affect the reduction of pain, and how this response may
modulate the magnitude of ASR and ERP responses.
Recent work has demonstrated that low-resolution brain electromagnetic tomography
(LORETA) is a valid tool for relevant pain research [31, 80]. Thus, a further aim of the present
study was to use LORETA analysis of auditory ERP waves to identify the influence of pain
reduction, hypnotizability, and pain expectation, in the activity of cortical regions involved in
auditory-startle processing.
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Materials and Methods
Ethics statement
The research was conducted according to the ethical standards of the American Psychological
Association (APA). Approval of this study was obtained from the Ethics Committee of the
Department of Psychology, La Sapienza University of Rome, Italy, on December 2, 2011. All
the participants gave their written consent to participate in the study, in accordance with the
Declaration of Helsinki.
Participants and measures of hypnotizability
Fifty-eight right-handed women volunteers were recruited through university courses by
advertisements. They were all new to hypnosis experience with the exception of one participant
who had experienced hypnosis one year before. Handedness was measured by the Italian ver-
sion of the Edinburgh Inventory Questionnaire [81, 82]. We included only healthy participants
free of medication who had no history of psychiatric or neurological disorders or any lifetime
history of hearing problems. The subjects were asked to refrain from smoking or drinking cof-
fee for at least three hours before the EEG recording. Only 53 women (M = 23, SD = 1.5 yr,
range 18–27 yr) participated in the study, since 5 participants were excluded for large eye-blink
and movements artifacts in the EEG record. The study consisted of two sessions. The first ses-
sion consisted in the administration of the Italian version of the Stanford Hypnotic Susceptibil-
ity Scale, Form C (SHSS:C, N = 53, M = 6.3, SD = 3.4; Md = 6.0) [83] to measure the
hypnotizability level of each participant. The second session (2 p.m. to 3 p.m.) consisted of a
pain manipulation treatment (to enhance placebo effect), followed by three treatments admin-
istered in both waking and hypnosis condition. Hypnosis was induced using the Stanford Hyp-
notic Clinical Scale (SHCS; N = 53, M = 2.4, SD = 1.7; Md = 2.0) [84] during which
electrophysiological recordings were obtained. Since the level of hypnotizability of each subject
(i.e., low, medium, or high hypnotizability) did not change across the SHSS:C and SHCS mea-
sures, only the measure of the SHSS:C was used for statistical analyses. More details for partici-
pant's selection are reported in the Section A in S1 Appendix.
Pain manipulation, treatments and pain/distress ratings
Fig 1 depicts a schematic representation of the second experimental session. Pain manipulation
phase consisted in the administration of the CCT for two times. Before of the first administra-
tion of the CCT participants were required first to rate their initial pain expectation for the
whole experimental testing (Pain Expectation) and then to hold, in their right hand, a thin plas-
tic cup full of frozen water at -10°C. This procedure served to measure pain threshold and, for
participants, to form a first experience of pain and distress sensation (Section B in S1 Appen-
dix). During the second CCT administration participants were deceived into thinking that a
sham analgesic cream (“Anedicaine Cream 13%”), smeared on the palm of their right hand,
was working to reduce their pain sensation [7, 12, 16, 85, 86] (Section C in S1 Appendix). They
were first informed that the "Anedicaine Cream" would have had its maximum effect after
eight minutes from the administration, and that the effect would be lost completely after 20
minutes. During the application of the cream to the surface of the palm and fingers of the right
hand, the participants were given a suggestion devoted to induce a reduction of pain sensation
(see Fig 1A and Section C in S1 Appendix). Eight minutes after the application of the cream,
participants were required first to rate their pain expectation and, then, to tightly hold a frozen
water cup for 3.7 minutes. At this point the temperature of the plastic cup was reduced from
-10°C to -6.5°C. Just after this manipulation, participants first rated their experienced pain and
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distress and then the level of cream efficacy (NRS). The manipulation procedure led partici-
pants to report a reduction of both pain and distress scores on the NRS (Pain: M = 23.2,
SD = 12.1, t = 9.7, p< 0.0001; Distress: M = 11.7, SD = 11.3, t = 6.4, p< 0.0001). The electrodes
were then attached to the participants for electrophysiological recordings. During waking, and
following the hypnotic induction (SHCS), each participant was subjected to the following three
separate treatments: (1) Baseline, no-painful/no-treatment, i.e., holding in the right hand a cup
full with a mixture of wax and iron filings at a temperature near body level of about 35°C; (2)
CCT, i.e., holding a cold cup at -10°C in the right hand [79] without any cream administration
(Pain); and (3) CCT plus sham cream with suggestion treatment (Section C in S1 Appendix)
for pain relief (Placebo). Somatic (eye blink) and ERP responses to acoustic startle probes were
elicited during the Baseline, Pain, and Placebo treatments in waking and hypnosis condition.
Before each painful treatment, participants rated their level of pain expectation (NRS), and
after each treatment they rated the level of the experienced pain and distress (NRS, Fig 1B and
Fig 1. Schematic representation of experimental design and procedure. Panel (a) displays Manipulation procedure including the initial Pain
Expectation rating, the measure of Pain Threshold, the administration of Sham Cream plus Verbal Suggestion and Pain Manipulation. In panel (b)
are shown the Baseline, Pain and Placebo treatments in waking condition. In panel (c) are shown the same treatments administered after the
hypnotic induction (Stanford Hypnotic Clinical Scale, SHCS). Treatments, within each participant, were administered in the same order in waking
and hypnosis condition, but both conditions and treatments were counterbalanced across participants. Before administration of pain and placebo
treatment, participants rated the level of pain expectation. Following each pain treatment, participants rated the intensity of experienced pain and
distress sensation. In panels (b) and (c), for each treatment, are displayed acoustic probes (115 dB, 40 ms) delivered to elicit startle blink responses.
doi:10.1371/journal.pone.0159135.g001
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1C). The sequence of waking and hypnosis conditions, as well as the order of presentation of
the three treatments, was counterbalanced across participants. However, within each partici-
pant, the order of the three treatments was held the same for both waking and hypnosis condi-
tions. The whole of the testing took approximately 11 min, 3.7 min for the Baseline and 3.7
min for the Pain and Placebo treatments. In addition, an inter-treatment relaxing interval of 3
min was given after each treatment. Following the administration of the “Anedicaine Cream" a
time period of 8 min was given to ensure an effect of the pharmacological treatment and then
the CCT was administrated (3.7 min). A recovery period of 6 min was given between waking
and hypnosis conditions. Before starting the hypnotic induction, participants were required to
rate their expectation and motivation to experience hypnosis using two separate NRS scales.
Following the hypnotic induction and hypnotic testing, paticipants were administered a frac-
tionation procedure (reverse counting from 20 to 1) devoted to enhance hypnosis depth [87].
After this procedure participants rated their hypnotic depth on a NRS scale.
Sham analgesic cream
The sham analgesic cream was a simple yellow and scented moisturizer. The smell was
obtained by mixing 5 drops of essential oil (tea tree oil) into 300 grams of cream. Participants
were told: “In this second session, we are interested in exploring the subjective reactions to
painful stimuli in both waking and hypnosis conditions. This study is part of an international
collaborative research study devoted to compare the pain reduction effects of a known analge-
sic cream on brain activity during intense acoustic stimulations. The cream consists of an active
pharmacological natural compound that has been prepared in our university hospital and
proved to have strong analgesic effects free from side effects. In this experiment, we are follow-
ing a double-blind procedure that includes a sham cream as a control and, for this reason, nei-
ther the experimenter nor the participants are aware of which ointment will be used.” We used
this experimental protocol to avoid the "analgesic cream" being seen as a sham treatment, since
the participants were all students in psychology courses. In this way, we tried to avoid any sur-
prise effect on the startle and ERP responses [88]. Although, in this way, we may have reduced
the placebo effect, we avoided bias effects caused by possible suspicions that the cream could be
a sham drug [89, 90]. After this introduction, participants were required to fill out the consent
form and a state anxiety questionnaire (STAI-Y1, State-Trait Anxiety Inventory by Spielberger
and colleagues [91]; Cronbach’s α for the STAI-Y1 in the present research was .85). Partici-
pants were informed about the difference between pain and distress sensation and then they
were required to rate their pain expectation on a 0 to 100 ‘Numeric Rating Scale’ (NRS) [92].
Acoustic startle stimuli
Acoustic startle stimuli were binaurally presented through headphones (Telephonics) and pro-
duced using the Wavelab-5.0 software. The acoustic startle stimulation consisted of three trial
blocks. Each block included the presentation of 24 acoustic stimuli and began with a 2 min
adaptation period consisting of 70 dB broadband noise (0–44 kHz), which continued as back-
ground noise throughout the session. Of the 24 acoustic stimuli, 10 were pulse-alone (PA) sti-
muli and 14 were pairs of acoustic stimuli, a prepulse followed by a pulse with a lead interval of
120 ms. In order to avoid habituation, i.e., reduced responding across stimulus type, PA and
prepulse-pulse (PP) stimuli were presented in pseudorandom order to ensure that there were
never more than two PA or PP in succession [93]. The interval between the PA and PP stimuli
varied between 7–10 seconds. PA startle stimuli were binaural acoustic white-noise probes
(115 dB, 40 ms duration, instantaneous rise time< 1 ms). PP stimulation consisted of two
white noise pulses, the prepulse (85 dB, 20 ms duration) and the pulse (115 dB, 40 ms), with a
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lead interval between the onset of the prepulse and the onset of the pulse stimuli of 120 ms.
The stimulus had an almost instantaneous rise time (< 1 ms). Since the CCT has a strong nega-
tive valence, which is known to increase over the course of time [94], in each trial block we
began to deliver the acoustic stimuli 30 s after the painful stimulation had started. Before start-
ing the EEG recording, additional four PA and four PP stimuli were delivered superimposed to
background noise. These served as habituation trials (1.5 min) and were not included in further
analysis. Initial startle responses are usually exaggerated in size. After a few trials, habituation
follows a more gradual course. Therefore it is common to exclude initial trials from further
analysis (‘‘habituation trials”) [93]. During the three treatments, participants were asked to
look straight ahead to a fixation point in the center of a 15-inch monitor.
Clinical studies that have used a prepulse of 85 dB and a 70 dB background noise (i.e., pro-
viding a signal-to-noise ratio of +15 dB) have shown that startle and prepulse inhibition
responses are sensitive indexes of individual differences in schizophrenia [95–97] and anxiety
spectrum diseases [98]. This method has been also found valid to detect individual differences
in anxiety [99] and hypnotic susceptibility [60] in nonclinical participants. When background
noise is not used, the prepulse and the pulses may be so salient that individual differences in
startle and prepulse inhibition do not appear in clinical and normal populations [100].
The ERP responses elicited by the startle probe of the prepulse-startle pair (lead interval of
120 ms) were partially overlapping with the ERPs elicited by the preceding prepulse. Thus, we
decided that the detection and measure the N100 and P200 waves must be done by visual
inspection of each complex waveform. Thus, due to the complexity of this scoring process pre-
pulse-pulse inhibition responses will be analyzed and reported later in another paper.
EEG/EMG recordings
EEG, EMG, and electro-ocular (EOG) activities were acquired using a 40-channel NuAmps
DC amplifier system (Neuroscan Inc.), set at a gain of 200, a sampling rate of 1000 Hz, and
with signals band-limited to 500 Hz. Data were recorded and stored on a computer running
Neuroscan Acquire 4.3 software. Electrode impedance was lower than 5 kO. The horizontal
EOG was monitored via a pair of tin electrodes placed 1 cm lateral to the outer canthus of each
eye, while the vertical EOG was monitored via a separate bipolar montage placed above and
below the center of the left eye.
Electrodes for EMG recording of the muscle orbicularis oculi were attached below the par-
ticipant’s right eye at an inter-electrode distance of 1.5 cm. EEG data were recorded from 30
scalp sites (Fp1, Fp2, F7, F8, F3, F4, FT7, FT8, T3, T4, FC3, FC4, C3, C4, CP3, CP4, TP7, TP8,
T5, T6, P3, P4, O1, O2, Fz, FCz, Cz, CPz, Pz, Oz) using a pure-tin electrode electro-cap and
were referenced to digitally linked ears (A1 + A2)/2 by Neuroscan Acquire setting. The ground
electrode was located 10 mm anterior to Fz. During the EEG recording, each signal was first
online filtered using 50 Hz notch filter. The EEG was then reconstructed into discrete, single-
trial epochs. For each stimulus, an EEG epoch length of 700-ms was used with a 200-ms pre-
stimulus baseline and a 500-ms time window following the acoustic stimulus onset. Epochs
were rejected from averaging if the amplitude exceeded ±75 μV, and eye blinks were corrected
using Gratton et al.’s procedure [101]. Additional movement artifacts were removed manually.
After removing artifacts, only responses to PA stimuli that used 6 or more epochs were
accepted for PA averaging in the present study [102].
Startle and ERPmeasures
The EMG signal was off-line filtered by a 28 Hz high-pass filter [103] using the Brain Vision
Analyzer 2.1.0. The raw signal was then rectified and integrated online with a time constant of
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10 ms [104]. The ASR was defined as the difference between the peak and baseline signal. EMG
signal was epoched within a 500 ms time window with a baseline of 200 ms prior to the onset
of the startle stimulus. Data were baseline corrected, visually inspected for artifact rejection,
rectified, and enveloped. A time window of 40–150 ms was used to detect ASRs. The occur-
rence of a startle was considered when there was at least an EMG value greater than 3 SD above
a 200 ms baseline mean (for details see [105]). Peak latency was defined as the point of maxi-
mal amplitude occurring within a time window of 40–150 ms after the pulse stimulus onset
[93]. Each response was manually confirmed and participants with more than 4 non-responses
were excluded from the study, according to the criteria of Braff and collaborators [106].
All EEG-averaged signals were digitally filtered (48-Hz low pass) and baseline corrected.
After baseline correction, two reliable ERP components, mainly pronounced at the central
recording site (Cz), were identified. The first component was the N100 (112.3 ± 9.8 ms), which
was quantified at Cz as the baseline-to-peak difference in voltage for the most negative peak
within a window of 80–150 ms following the startle tone onset. The second component was the
positive P200 (197.4 ± 18.4 ms), which was quantified at Cz, as the most positive peak in a win-
dow of 165–240 ms.
LORETA source localization analysis
The LORETA-KEY software package (version v20150415 by R. D. Pascual-Marqui, The KEY
Institute for Brain-Mind Research, Zurich, Switzerland; https://www.uzh.ch/keyinst/loreta)
was used for source localization analysis of the ERP responses. This method enables the spatial
identification and analysis of brain cortical activity via conventional EEG recordings [107–110]
and has been found useful for the analysis of different time segments of ERPs [80, 111, 112].
LORETA computes current density (μA/mm2, i.e., the amount of electrical current flowing
through a solid) without assuming any number of active sources [113]. The LORETA solution
space (i.e., the locations in which sources can be found) is composed of 6239 cubic elements
(“voxels,” 5 mm3) and is limited to cortical gray matter and hippocampi, as defined by a digi-
tized MRI available from the Montreal Neurologic Institute (MNI; Montreal, Quebec, Canada)
[114–119]. Before performing LORETA analyses, the EEG was resampled at 256 Hz.
LORETA source localization was calculated using coordinates of the 30 electrode positions
for every subject at the mean N100 and P200 peaks for the PA trials. For wave source recon-
structions and to detect differences in source activity, the subtractions of ERP traces between
LH and HH and between high vs. low pain expectation participants were assessed using LOR-
ETA using time intervals of 80–120 ms and 170–210 ms, respectively, for the N100 and P200
waves. It is important to note that this localization is not a complete listing of all significantly
different cortical areas, but is a listing of the local maxima of these differences.
Statistical analyses
The analysis of the contribution of hypnotizability and rating measures to pain intensity and
distress reduction was conducted in two steps. In the first step, zero-order correlations were
obtained between hypnotizability (SHSS:C), self-rating measures of hypnotic depth, initial pain
expectation, cream efficacy, and expectation and motivation to hypnosis versus pain/distress
reductions (obtained by subtracting pain/distress rated for placebo from that rated for pain
treatment) during waking and hypnosis. The significance of these correlations was assessed by
using the bias-corrected bootstrap method, which is effective in controlling for type 1 errors
associated with multiple comparisons [120]. This bootstrap analysis was performed in two
steps. In the first step, 5000 new samples were generated by random re-sampling with replace-
ments from the available data under the condition that each of the 5000 samples had the same
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size as the original. In each sample, we first computed zero-order correlations of each variable
of interest separately within pain and distress reductions. Critical values for the upper and
lower 95% bias-corrected confidence limits for all the zero-order correlation coefficients were
then estimated. All coefficients with an associated confidence interval that did not include zero
were considered statistically significant (p< 0.05).
Separate ANCOVAs (glm procedure, SAS 9.2) were then performed to test the effect of
experimental manipulation on pain and distress scores wherein Hypnotizability, Pain Expecta-
tion, and Cream Efficacy were included as continuous between-subjects factors (covariates),
and Treatment (Pain, Placebo) and Condition (Waking, Hypnosis) as within-subjects factors.
EMG startle amplitude measures was analyzed using a repeated measures ANCOVA with
treatment (Baseline, Pain, Placebo) as within-subjects factors and Hypnotizability, Pain Reduc-
tion level, and Pain Expectation as continuous between-subjects factors (covariates). N100 and
P200 peak amplitude measures were separately analyzed by using a similar ANCOVA design
that focused on 4 midline recording sites (i.e., frontal, central, parietal, and occipital sites), with
hypnotizability, Pain reduction level, and Pain expectation as continuous between-subjects fac-
tors.The Huynh–Feldt epsilon correction of significance levels was applied when necessary
[121]. Post-hoc contrasts analyses were used when necessary (α = .05). As a graphic illustration
of the direction for the main or interaction effects involving Pain Reduction Hypnotizability,
or Pain Expectation on dependent measures of interest, data were grouped for the significant
factor and displayed if necessary. A median split was used to form groups with high and low
levels of hypnotizability (HH and LH; Md = 6.0). A similar method was used to group high and
low levels of Pain Expectation (Md = 50.0) and Pain Reduction (Md = 5.0).
Results
Manipulation: Pain expectation versus Pain and Distress ratings
In the first administration of CCT (Fig 1A), the relation between pain expectation and pain
threshold was not significant (r = 0.102, p> 0.05, Bootstrap: 95%, CI -.06 to .27). Moreover,
pain expectation was highly correlated with pain perception, but not significantly with distress
(pain: r = 0.50, p< 0.0001; Bootstrap: 95%, CI .35 to .62; distress: r = 0.254, p> .05, Bootstrap:
95%, CI .08 to .43). In the second CCT administration (manipulation phase), the correlation
between pain expectation and pain perception was quite reduced, although it remained signifi-
cant (pain: r = 0.28, p< 0.05, Bootstrap: 95%, CI .12 to .44), but these measures for distress
were not significant (distress: r = 0.180, p> .05, Bootstrap: 95%, CI -.01 to .34). In addition, as
expected, the correlation between cream efficacy and pain perception was significant and nega-
tive (pain: r = -0.40, p< 0.01; Bootstrap: 95%, CI .32 to .58).
Hypnotizability and rating measures
Descriptive statistics and Pearson’s correlations, along with their 95% associated bootstrapped
confidence intervals, of pain/distress reductions during waking and hypnosis (i.e., calculated
by subtracting ratings/distress scores obtained during Placebo from those during Pain treat-
ment), hypnotizability, pain expectation, hypnosis depth, cream efficay, expectation and moti-
vation to experience hypnosis, are presented in Table 1. Pain expectation, as well as
hypnotizability and cream efficacy, were significantly correlated with both pain and distress
reductions during Placebo treatment in waking condition, but these correlations did not
reached the significance level during hypnosis (Table 1).
State anxiety did not evidence any significant correlation with hypnotizability, pain expecta-
tion, and pain/distress ratings (all ps> .05).
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ANCOVA for pain intensity ratings using Hypnotizability, Pain Expectation and Cream
Efficacy scores as covariates yielded a significant interaction of Treatment x Pain-Expectation
(F(1,49) = 5.94, p = 0.016). Follow-up contrast analysis showed that pain rating was signifi-
cantly higher for pain than placebo treatment in high pain expectation participants (p< .05,
see Fig 2A).
In addition, the interaction Treatment x Hypnotizability was also significant (F(1,49) =
5.74, p = 0.020), indicating that pain rating was significantly higher during pain than placebo
treatment in HH participants (Fig 2B). The main effect for Treatment was near the significance
level (F(1,49) = 3.85, p = 0.056), showing a trend towards a lower pain rating during placebo as
compared to pain treatment.
The ANCOVA for distress ratings yielded a significant interaction of Hypnotizability x Con-
dition (F(1,49) = 5.34, p = 0.025) and of Condition x Treatment x Hypnotizability (F(1,49) =
4.48, p = 0.039). Contrast analysis for the first effect indicated a significant distress reduction, in
HH participants, during hypnosis compared to waking condition (p< 0.05, Fig 2C). The second
effect indicated that HH participants, in both waking and hypnosis conditions, had a significant
distress reduction for placebo versus pain treatment, while LH participants did not disclose sig-
nificant changes between treatments and conditions (Fig 2D). No significant effects involving
pain expectation were found for distress ratings.
Startle eye-blink response
ANCOVA on peak amplitude of eye-blink response to PA startle probe yielded a significant
main effect for Pain Reduction (F(1,49) = 8.68, p = .0049), which indicated a higher ASR in
high pain reducers as compared to low pain reducers (Fig 3A). In addition, the interaction of
Treatment x Pain Reduction and of Treatment x Pain Reduction x Condition were both
Table 1. Correlation (N = 53) of Pain and Distress reductions (Pain minus Placebo treatment) duringWaking and Hypnosis with SHSS:C, Pain
Expectation, Cream Efficacy, Expectation andMotivation to Hypnosis rating scores. Means (M) and Standard Deviations (SD) for each variable are
reported in the bottom and right of the table.
Pain Reduction Distress Reduction
Variable Waking Hypnosis Waking Hypnosis Mean and SD
SHSS:C 0.29* 0.20 0.28* 0.17 M = 6.32; SD = 3.41
95%CI (0.08, 0.46) (-0.05, 0.38) (0.08, 0.45) (-0.01, 0.33) -
Pain Expectation 0.45† 0.19 0.38** 0.05 M = 52.64; SD = 21.70
95%CI (0.24, 0.59) (-0.01, 0.38) (0.11, 0.54) (-0.17, 0.26) -
Hypnosis Depth 0.25 0.19 0.13 0.38** M = 60.47; SD = 20.32
95%CI (-.03, .39) (-.04, .37) (-0.07, 0.36) (0.23, 0.50) -
Cream Efficacy 0.38** 0.15 0.27* 0.02 M = 45.23; SD = 31.96
95%CI (0.19, 0.54) (-0.04, 0.34) (0.11, 0.39) (-0.18, 0.26) -
Expectation to Hypnosis 0.31* 0.32* 0.27* 0.22 M = 62.89; SD = 20.32
95%CI (0.16, 0.41) (0.14, 0.44) (0.12, 0.39) (-0.00, 0.36) -
Motivation to Hypnosis 0.26 0.13 0.26 -0.03 M = 82.83; SD = 17.25
95%CI (-0.05, 0.38) (-0.13, 0.30) (-0.01, 0.34) (-0.21, 0.13) -
Mean 9.06 6.62 6.60 3.62 -
SD 14.60 14.61 2.08 11.50 -
* p < 0.05
** p < 0.01
† p < 0.001
doi:10.1371/journal.pone.0159135.t001
Placebo Analgesia in Waking and Hypnosis in HealthyWomen: Auditory Startle and ERP Responses
PLOS ONE | DOI:10.1371/journal.pone.0159135 August 3, 2016 10 / 27
significant (F(2,98) = 10.95, p< 0.0001, and F(2,98) = 11.30, p< 0.0001, respectively). Follow-
up contrasts analysis for the first interaction indicated that during baseline and placebo treat-
ments high pain reducers had a larger startle peak that low pain reducers (p< 0.001), while for
pain treatment there were no significant differences between groups (Fig 3B). The second inter-
action effect indicated that pain reducers, in waking baseline and placebo treatments, had sig-
nificantly higher eye-blink amplitude that low reducers (p< 0.05). However, during hypnosis
this difference was more pronounced compared to waking condition (p< 0.001, Fig 3C).
Finally, the interaction of Hypnotizability x Treatment was also significant (F(2,98) = 3.39,
p< 0.05). This effect indicated that HH participants, during the baseline, had a larger ASR
than LH ones. During both pain and placebo treatments this difference between hypnotizabil-
ity groups was not significant (see Fig 3D). No other effects were significant.
Fig 2. Mean and standard errors of pain (panels a, b) and distress ratings (panels c, d), as measures of sensory-discriminative and
affective-motivational components of pain. Panel (a) displays pain scores in high and low pain expectation (Hi P.Expect and Lo P.Expect) and
panel (b) in high and low hypnotizable participants (HH and LH) during pain and placebo treatments. Panel (c) shows distress ratings of waking
and hypnosis conditions in high and low hypnotizable subjects (HHs and LHs). Panel (d) depicts distress ratings during pain and placebo
treatments in waking and hypnosis conditions. *p < 0.05, **p < 0.01.
doi:10.1371/journal.pone.0159135.g002
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N100 and P200 peak amplitudes to PA startle
ANCOVA performed on N100 midline amplitudes scores elicited by PA stimuli yielded a sig-
nificant main effect of Pain Reduction (F(1,49) = 4.78, p = 0.02). Follow-up contrasts indicated
that high pain reducers had a larger N1 peak on frontal recordings (Fz) than low pain reducers
(M = 25.1 μV, SD = 3.5 μV vs. M = 19.4 μV, SD = 1.9 μV, p< 0.05). This difference is displayed
in Fig 4A.
ANCOVA performed on P200 midline amplitudes yielded a main effect for Pain Reduction
(F(1,49) = 4.09, p = 0.049). Follow-up contrasts indicated that high pain reducers had a larger
N1 peak on central recordings (Cz) than low pain reducers (M = 36.2 μV, SD = 2.1 μV vs.
M = 32.5 μV, SD = 1.6 μV, p< 0.05; see Fig 4B).
The second order interaction of Hypnotizability x Condition and the third order interaction
of Hypnotizability x Condition x Treatment were both significant (F(1,49) = 5.05, p = 0.029,
and F(2,98) = 3.15, p = 0.044, respectively). Contrasts analysis indicated that, during placebo
treatment in waking condition, the HH participants had a larger P200 wave than the LH ones
(F(1,49) = 5.63, p = 0.022; M = 33.7 μV, SD = 5.7 μV vs. M = 25.5 μV, SD = 4.8 μV) while, for
Fig 3. Time course of a typical eye blink (EMG) startle response in high pain reducers and low pain reducers (panel a). Mean startle
amplitudes and standard errors during Baseline, Pain, and Placebo treatments in high pain reducers and low pain reducers (panel b).
Startle amplitude values across the three treatments in waking and hypnosis (panel c). Mean startle amplitudes across treatments in
high and low hypnotizable participants (Panel d). *p < 0.05, **p < 0.01, ***p < 0.001.
doi:10.1371/journal.pone.0159135.g003
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Fig 4. ERPs of the most sensitive scalp sites (Fz and Cz) to auditory startle probes in high and low pain
reducers (left panel a). Averaged scalp topography of N100 (panel a) and P200 wave (panel b) in high and
low pain reducers (t-test maps are reported on the right side). In panel (c) is shown the averaged scalp
topography of the P200 peak in high hypnotizable (HHs) and low hypnotizable (HHs) participants during
Placebo treatment in waking and hypnosis conditions. t-Test map comparing HHs vs. LHs (maps on the right
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placebo treatment during hypnosis, this difference between hypnotizability groups was even
more pronounced (F(1,49) = 8.01, p< 0.01; M = 35.5 μV, SD = 6.7 μV vs. M = 24.5 μV,
SD = 4.1 μV; see Fig 4C). No other significant effects were found.
LORETA source localizations and individual differences
To test for statistically significant differences in regional brain activation between groups, sepa-
rate t-tests of high vs. low levels in Pain Reduction and Hypnotizability were performed on
sLORETA waveforms derived from ERP waves.
For Pain Reduction, we found that high pain reducers had a significantly higher activation
at 105 ms (i.e., a maximal negative t value in the time window of N100) in the left paracentral
lobule of the frontal lobe (BA5), the left postcentral gyrus of the parietal lobe (BA3), and in the
sub-gyral of the parietal lobe (upper panel of Fig 5 and Table 2). High pain reducers also
showed a greater activation at 188 ms (i.e., a maximal positive t value in the time window of
P200 wave) in the cingulate gyrus of the limbic lobe (BA24, BA23, and BA31). These regions
are mapped in the lower panel of Fig 5 and reported in the bottom of Table 2.
In terms of individual differences in Hypnotizability, we found that, during placebo treat-
ment in waking condition, HH participants, compared to LH ones, had a significantly lower
activity at 90 ms (N100 wave) in the middle and superior temporal gyri (BA21, BA22, BA38) of
the right temporal lobe. Interestingly, during placebo treatment in hypnosis significant differ-
ences between hypnotizability groups were found at 110 ms in the cingulate gyrus (BA24), the
medial frontal gyrus (BA6), and paracentral lobule (BA31). These regional differences are dis-
played in Fig 6A and 6B and upper section of Table 3. For the P200 wave, we found that during
placebo in waking condition HH, compared to LH participants, had a significantly higher
activity at 175 ms in the left and central cingulate gyrus (BA24), while during hypnosis these
differences between hypnotizability groups were found at 173 ms in the central and right cin-
gulate gyrus (BA24). These differences are shown in Fig 6C and 6D and in the lower section of
Table 3.
Discussion
In the current study we found that higher pain expectation, rated before participants had expe-
rienced experimental pain for the first time (Fig 1A), was associated with higher levels of pain
reduction through placebo treatment in waking condition (Table 1, and Fig 2A). Although we
have not found another study reporting this relation, this effect is sometimes observed in a clin-
ical context and can be reasonably understood if we assume that an inhibitory conservative
mechanism is operating in order to fit with the expected painful event. In contrast, during hyp-
notic placebo analgesia the association of pain expectation with pain or distress reduction was
weakened and not significant (Table 1). We conceived this result assuming that hypnosis dis-
rupted the upper-mentioned significant associations found in waking condition. This result
supports previous findings suggesting that placebo and hypnosis involve, at least to some
extent, different processes of top-down regulation [19]. This observation also corroborates our
previously reported pain-hypnosis ERP findings [31]
In terms of hypnotic susceptibility, our results are consistent with a number of previous
reports showing that HH individuals are more responsive to suggestions for pain reduction
side) clearly shows for waking Placebo a larger P200 amplitude in the frontal left hemisphere, while for Placebo
treatment during hypnosis this left-hemisphere difference was distributed from frontal to occipital sites (p < 0.05).
doi:10.1371/journal.pone.0159135.g004
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[33, 78, 87, 122–126] than LH ones (Fig 2B). In addition, during hypnosis we found an
enhanced distress reduction compared to the waking condition (Fig 2C).
In terms of eye-blink, N100, and P200 startle responses, we did not find significant differ-
ences between pain and placebo treatments compared to baseline. These lacking effects parallel
Deuter and colleagues’ startle findings [73] and deserve further explanation. It has been
reported that directing attention to the startle-eliciting stimulus can increase the startle
response, while directing attention to a painful stimulus can reduce startle magnitude [127].
Attentional and emotional factors interact and may work in opposite directions, making the
net effect on startle responsiveness difficult to predict [128]. If they are equal in size and point
in opposite directions, no observable net effect would appear. This may have been the case for
the EMG and ERP startle responses we detected across treatments. However, we also found
that pain reducers reported significant enhancements of EMG, N100, and P200 amplitudes to
the startle probe across all experimental conditions (Fig 3A, 3B, 3C and Fig 4). This difference
Fig 5. LORETA parametric maps comparing N100 peak (top panel) and P200 peak (bottom panel) of the ERPs to auditory startle probes
of high vs. low Pain reducers.Note that high pain reducers showed a higher activation in the left paracentral lobule of the frontal lobe (BA5) and
in the postcentral and sub-gyral gyri lobule of the parietal lobe (BA3 and BA40) at 105 ms (N100 peak). For the P200 peak, high pain reducers had
a higher activation at 188 ms in the cingulate gyrus of the limbic lobe (BA24, BA23, and BA31); coordinates are shown in Table 2.
doi:10.1371/journal.pone.0159135.g005
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between high and low pain reducers for the N100 was more frontally and, for the P200, more
centrally distributed (see t maps in Fig 4A and 4B). These findings corroborate the hypothesis
that relief of subjective painfulness is highly pleasant and rewarding [129, 130] and that less
attentional resources were directed to the cold-pain stressor, making attention more direct
towards the startle-eliciting stimulus. This indirect modulation in selective attention, as a con-
sequence of pain reduction, may have enhanced startle and ERP responses [54, 127, 131–137].
Interestingly, these findings are in line with the observations suggesting that brain activity
increases in the prefrontal cortex during both placebo [26, 27, 138–141] and hypnosis treat-
ments for pain reduction [32–35]. The involvement of prefrontal cortex indicates that cognitive
evaluation and attention are most likely to play an important role in pain relief. Overall, we
found that during placebo treatment in waking the HH, compared to LH participants, had a
significantly higher P200 wave across midline and frontal leads in the left hemisphere, while
during placebo treatment in hypnosis this difference was spread throughout the left hemi-
sphere (i.e., contralaterally to the side of painful stimulation; t maps Fig 4C). These differences
between HH and LH groups could be due to the fact that the HH, but not LH, had significant
pain/distress reductions to placebo treatment during waking and, even more pronounced dur-
ing hypnosis. This could have enhanced saliency of the auditory stimulation and, thus, reori-
ented attention to the most significant alerting stimulus [137], a cognitive-control function
attributed to the left frontal cortex [142]. In addition, during hypnosis the activation involved
the whole left hemisphere including the occipital cortex. These results parallel original findings
suggesting that waking placebo treatment is associated to an increased activity in the prefrontal
cortex [26, 138–141, 143], while hypnotic placebo analgesia is associated to activity changes,
other than in the prefrontal cortex, throughout the left-hemisphere including occipital cortex,
which is concerned with mental imagery processing [32–34, 144].
Our interpretation of the present findings is also supported by previous reports showing
that LH individuals, compared to the HH ones, usually possess weaker abilities to focus and
sustain their attention as well as to pop out, from the environmental context, irrelevant stimuli
and these differences are reflected in underlying brain dynamics [31, 61, 145]. This conclusion
fits well with Horton and colleagues’ neuroimaging findings of a larger rostrum of corpus
Table 2. MNI coordinates and Brodmann areas (BA) of statistically stronger cerebral activation in High Pain Reducers (N = 25) compared with Low
Pain Reducers (N = 28) for the N100 (max BA at 105 ms) and P200 waves (max BA at 188 ms) elicited by pulse-alone startle.
ERP X Y Z t(max)* BA Lobe Region No. Voxels p<0.05
N100 -20 -45 55 -3.85 L5 Frontal Paracentral Lobule 25
-20 -40 60 -3.82 L3 Parietal Postcentral Gyrus 5
-25 -40 55 -3.69 L40 Parietal Sub-Gyral 4
P200 -5 -5 30 4.99 L24 Limbic Cingulate Gyrus 53
0 -5 35 4.98 C24 Limbic Cingulate Gyrus 11
5 -5 35 4.84 R24 Limbic Cingulate Gyrus 36
-5 -15 30 4.80 L23 Limbic Cingulate Gyrus 21
0 -15 30 4.78 C23 Limbic Cingulate Gyrus 6
5 -15 30 4.80 R23 Limbic Cingulate Gyrus 10
-10 -25 40 4.35 L31 Limbic Cingulate Gyrus 17
0 -30 35 4.33 C31 Limbic Cingulate Gyrus 10
20 -30 45 4.35 R31 Limbic Cingulate Gyrus 18
*t-crit. = 3.65, p < 0.05; t-crit. = 4.48, p < 0.01
Note: For N100 wave, a negative value of t indicates a higher CSD for High Pain Reducers than Low Pain Reducers. For P200 wave, a positive value of t
indicates a higher CSD for High Pain Reducers than Low Pain Reducers.
doi:10.1371/journal.pone.0159135.t002
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Fig 6. LORETA parametric maps comparing N100 peak of high vs. low hypnotizable participants (HHs
vs. LHs) in waking (a) and hypnosis conditions (b). Similar comparisons were done for the P200 peak
in waking (c) and hypnosis (d). For the N100 peak note that HHs compared to HHs during waking showed a
lower activation in the right middle and superior temporal gyri (BA21, BA22, BA38) at the 91 ms time frame
(N100 peak) while, during hypnosis, the maximal differences between hypnotizability groups were found at
Placebo Analgesia in Waking and Hypnosis in HealthyWomen: Auditory Startle and ERP Responses
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callosum in HH participants, compared to LH ones, and with studies indicating a more effi-
cient mechanism of sensory gating in the former, rather than the latter [58, 60].
Our LORETA analysis of the N100 and P200 ERP waves disclosed that the left-paracentral
lobule in the frontal lobe (BA5), the left-postcentral (BA3), and the left-sub-gyral in the parietal
lobe (BA40) were significantly more activated in high pain reducers at 105 ms (N100 wave)
than low pain reducers. In addition, these participants for the P200 wave had the maximal acti-
vation at 188 ms in the anterior cingulate (BA24) and posterior cingulate (BA23 and BA31)
gyrus of the limbic lobe (see Fig 5 and Table 3). These regional findings, together with N100
and P200 ERP findings (Fig 4), indicated that pain reduction, in an early stage of stimulus-
driven attentional processing, requires the activation of the left frontal and parietal lobes,
whereas in a later stage of processing requires the activation of anterior and posterior cingulate
gyres. This observation is corroborated by prior neuroimaging and animal research findings
indicating that candidate structures for the modulation of startle amplitudes are the prefrontal
cortex, caudate nucleus, cingulated cortex, and thalamus [40, 146–149].
In terms of individual differences in hypnotizabiliy, our LORETA analysis highlighted that
in HH, compared to LH participants, waking placebo treatment produced an early decreased
activity in the right middle and superior temporal gyrus (90 ms from tone onset, N100 wave;
110 ms in the cingulate gyrus (BA24), in the medial frontal gyrus (BA6), and paracentral lobule (BA31). For
the P200 peak note that HHs compared to HHs during both waking and hypnosis conditions showed higher
activations in the cingulate gyrus of the limbic lobe (BA24) at about a 175- ms time frame. Coordinates are
shown in Table 3.
doi:10.1371/journal.pone.0159135.g006
Table 3. MNI coordinates and Brodmann areas (BA) of statistically lower cerebral activation for the N100, and higher activation for the P200 wave,
in High Hypnotizable (HH, N = 25) compared to Low Hypnotizable participants (LH, N = 28) during Placebo treatment in Waking and Hypnosis con-
ditions, as elicited by pulse-alone startle. The statistically stronger activation for the N100 (Waking: 91 ms, Hypnosis: 110 ms) and P200 (Waking: 175
ms, Hypnosis: 173 ms) is reported.
Placebo Analgesia X Y Z t(max)* BA Lobe Region No.Voxels p<0.05
Waking
N100 (91 ms) 60 5 -10 4.08 R21 Temporal Middle Temporal Gyrus 7
60 5 -5 4.01 R22 Temporal Superior Temporal Gyrus 10
55 5 -10 4.00 R38 Temporal Superior Temporal Gyrus 6
Hypnosis
N100 (110 ms) -5 -10 50 5.09 L24 Limbic Cingulate Gyrus 11
0 -5 45 4.70 C24 Limbic Cingulate Gyrus 4
10 -10 45 4.75 R24 Limbic Cingulate Gyrus 8
-5 -15 55 4.87 L6 Frontal Medial Frontal Gyrus 7
5 -10 55 5.00 R6 Frontal Medial Frontal Gyrus 10
-5 -15 50 4.87 L31 Frontal Paracentral Lobule 4
Waking
P200 (175 ms) -5 -5 35 3.92 L24 Limbic Cingulate Gyrus 11
0 0 35 3.79 C24 Limbic Cingulate Gyrus 3
Hypnosis
P200 (173 ms) 0 15 30 3.82 C24 Limbic Cingulate Gyrus 2
5 15 30 3.67 R24 Limbic Cingulate Gyrus 2
*Waking t-crit. = 3.94, p < 0.05; t-crit. = 4.33, p < 0.01; Hypnosis t-crit. = 3.61, p < 0.05; t-crit. = 4.30, p < 0.01
Note: For the N100 wave, a positive value of t indicates that HH show lower CSD than LH participants. For the P200 wave, a positive value of t indicates a
higher CSD for HH than LH participants.
doi:10.1371/journal.pone.0159135.t003
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BA21, BA22, and BA38, see Fig 6A and Table 3). This effect was followed by a late increased
activity in the ACC (175 ms, P200 wave; Fig 6C and Table 3). Hypnotic placebo analgesia in
HH, compared to LH participants, disclosed an early (110 ms, N100 wave) decreased activity
in the ACC (BA24), medial frontal gyrus (BA6), and left-paracentral lobule (BA31; see Fig 6B
and Table 3). Hypnotic placebo analgesia, in a later processing stage (175 ms, P200 wave),
showed an increased activity in the ACC (Fig 6C and 6D and Table 3). It is interesting to note
that differences in cortical regional activity between waking and hypnosis placebo were found
in an early processing stage from the startle probe onset. That is, waking placebo showed an
earlier inhibition in the right temporal lobe, while hypnotic placebo an earlier inhibition (110
ms) in both frontal and ACC regions. In addition, in a late processing stage common to both
waking placebo and hypnotic placebo analgesia was the enhanced activity in the ACC.
Research has shown that these cortical regions are part of a pain responsive network (i.e.,
somatosensory cortex, ACC, insula, perigenual cortex, pre-supplementary motor cortex, thala-
mus, and prefrontal cortex) [141, 150–152] whose activity is modulated by the ongoing pain
experience associated with hypnotic analgesia [20, 32, 33, 58, 153, 154]. Thus, we think that
regional differences in electro cortical activity, found between hypnotizability groups, reflect
the higher pain/distress reduction reported by HH participants. Considering that both the
N100 and P200 waves are believed reliable measure of sensory gating [37, 155, 156], these find-
ings can suggest a more efficient sensory gating in HH in comparison to LH participants, and
indicate the important role of the right temporal-frontal lobe and ACC in the regulation of this
function.
The present results extend current findings on hypnotic modulation of brain activity in a
nonclinical sample [31, 33, 157, 158] and support the view that the effects of placebo and hyp-
nosis on pain relief are, at least to some extent, separate processes [19, 27, 32–35]. However, it
is important to underline that current source findings are purely speculative and must be con-
sidered with caution, since they were obtained using only 30 scalp electrodes and the modeling
is based on a standard head model (instead of individual MRI data). With a weaken spatial res-
olution, there is a smaller chance that LORETA will be able to separate two closely spaced
sources [159]. Another limitation of the current study is that our findings are restricted to
women participants and, thus, cannot be generalized to men. Thus, further studies are neces-
sary to validate our findings using an enhanced spatial resolution and by considering gender,
attention, and heterogeneity of hypnotizability as potential factors influencing somatic and
electrocortical startle responses during placebo analgesia in waking and hypnosis.
Conclusion
The present findings are in line with prior reports that the placebo treatment in both waking
and hypnosis condition can reduce pain and distress perception. Moreover, they show that
hypnosis is not equal to common placebo in terms of brain activity, thus questioning the
hypothesis that the pain reducing properties of hypnosis are just one form of placebo effect.
We found that higher pain expectation was associated with higher levels of pain reduction
through placebo treatment in waking condition, but during hypnosis this association was
under the significance level. We thought that this observation supports the hypothesis that pla-
cebo analgesia in waking and hypnosis reflects two different top-down processes [19].
Moreover, we have demonstrated that pain reduction induces an enhancement of EMG
startle, a larger N100 wave at frontal sites, and P200 wave at central sites. These findings sug-
gest that pain relief, being highly rewarding, makes that more processing capacity is available
to process auditory startle probes. The validity of this explanation is also supported by our
observation that in HH, compared to LH participants, placebo analgesia in waking condition
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enhances the activity in the prefrontal cortex [26, 27, 138–141] while, during placebo treatment
in hypnosis, this difference involved the left frontal cortex and the posterior left hemisphere
including occipital cortex, which is associated with mental imagery processing [32–34, 144].
Our LORETA analyses have highlighted that, in HH participants, waking placebo analgesia
is characterized by an earlier decreased activity in the right temporal cortex (N100 wave), fol-
lowed by a late increased activity in the ACC (P200 wave). During hypnosis, placebo analgesia
is characterized by an earlier reduced activity in the medial frontal cortex and ACC (N100
wave), followed by a late increased activity in the ACC (P200 wave). These cortical regions are
part of the previously described pain processing network [141, 150–152]. The present study
extends original findings on hypnotic modulation of brain activity in a normal sample [31, 33,
157, 158] and shows that hypnotic placebo analgesia differs from common placebo analgesia in
respect to pain experience and brain functioning.
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